4-amino-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran-6-carbonitrile | 89080-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4-amino-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran-6-carbonitrile
• 英文别名: 6-cyano-3,4-dihydro-2,2-dimethyl-trans-3-hydroxy-4-amino-2H-1-benzopyran；6-Cyano-3,4-dihydro-2,2-dimethyl-trans-4-amino-2H-benzo[b]pyran-3-ol；6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-amino-2H-1-benzopyran-3-ol；trans-4-amino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-1benzopyran-3-ol；trans-4-amino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzopyran-3-ol；(cis)-4-Amino-6-cyano-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran；4-amino-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
• CAS: 89080-70-6
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: APHWBGUCQBONMO-UHFFFAOYSA-N

物化性质

• 沸点：
  359.4±42.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran-6-carbonitrile 在 吡啶 、 4-二甲氨基吡啶 、 sodium hydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 242.0h， 生成
  参考文献：
  名称：

  Wolf; Weiss-Greiler; Wolschann, Pharmazie, 1996, vol. 51, # 11, p. 836 - 839

  摘要：

  DOI：
• 作为产物：
  描述：

  4-羟基苯甲腈 在 N-溴代丁二酰亚胺(NBS) 、 氨 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 4-amino-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran-6-carbonitrile
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY
  [FR] COMPOSITIONS ET PROCÉDÉS POUR UNE THÉRAPIE PAR CROMAKALIM À LIBÉRATION PROLONGÉE

  摘要：

  Extended-release pharmaceutical compositions comprising a biodegradable microparticle, nanoparticle or other polymeric formulation of Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof are provided with advantageous properties for in vivo delivery to a patient in need thereof. The extended-release formulations overcome historic obstacles in cromakalim, including levcromakalim, delivery.

  公开号：

  WO2023018958A1

文献信息

• Bicyclic compounds with pharmaceutical activity
  申请人：SmithKline Beecham plc,

  公开号：US05908860A1

  公开（公告）日：1999-06-01

  This invention relates to the method of treatment and/or prophylaxis of anxiety and/or disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy, using compounds of the formula (Ia): ##STR1##

  这项发明涉及使用式(Ia)的化合物治疗和/或预防焦虑和/或可用抗惊厥药物治疗和/或预防的疾病，如癫痫的方法。
• NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS
  申请人：Zhang Xuqing

  公开号：US20070049556A1

  公开（公告）日：2007-03-01

  The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.

  本发明涉及新型苯并吡喃衍生物，含有它们的药物组合物以及它们在治疗与钾通道相关的疾病中的应用。
• Novel chroman derivatives active on the central nervous system, their
  申请人：Sanofi

  公开号：US05082858A1

  公开（公告）日：1992-01-21

  Compounds of the formula ##STR1## in which: Z represents a halogen or a cyano, acetyl, trifluoroacetyl, nitro, C.sub.1 -C.sub.4 alkylthio, carboxyl, phosphono, dialkoxyphosphonyl or alkoxycarbonyl group, the alkylthio and alkoxy groups containing from 1 to 3 carbon atoms; R.sub.1 denotes a hydroxyl group and R.sub.2 represents hydrogen, or R.sub.1 and R.sub.2 taken together form an additional bond between the carbon atoms by which they are carried; and R.sub.3 represents a group NH--X--R.sub.4, in which X denotes a direct bond or an SO.sub.2 group and R.sub.4 represents a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group OAlk, Alk denoting a C.sub.1 -C.sub.4 alkyl group; a group --S--R.sub.5, in which R.sub.5 represents a C.sub.1 -C.sub.4 alkyl group, a C.sub.3 -C.sub.7 cycloalkyl or a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group AlOk, Alk denoting a C.sub.1 -C.sub.4 alkyl group; or R.sub.5 denotes a group --AlkN(Alk).sub.2 in which Alk is as defined above; or a group SO.sub.2 R.sub.5, in which R.sub.5 is as defined above, and the salts which the compounds of formula (I) are capable of producing with pharmaceutically acceptable acids when the substituent R.sub.3 comprises an amino group.

  式为##STR1##的化合物中：Z代表卤素或氰基，乙酰基，三氟乙酰基，硝基，C.sub.1 -C.sub.4烷基硫基，羧基，膦酸基，二烷氧基膦酰基或烷氧羰基，烷硫基和烷氧基含有1至3个碳原子；R.sub.1代表羟基，R.sub.2代表氢，或R.sub.1和R.sub.2一起形成它们所携带的碳原子之间的额外键；R.sub.3代表NH--X--R.sub.4基团，其中X代表直接键或一个SO.sub.2基团，R.sub.4代表未取代或经卤素、硝基、C.sub.1 -C.sub.4基团、三氟甲基基团、氨基、--N(Alk).sub.2基团、--COOAlk基团或OAlk基团取代的苯基团，其中Alk代表C.sub.1 -C.sub.4烷基；一个--S--R.sub.5基团，其中R.sub.5代表C.sub.1 -C.sub.4烷基、C.sub.3 -C.sub.7环烷基或未取代或经卤素、硝基、C.sub.1 -C.sub.4基团、三氟甲基基团、氨基、--N(Alk).sub.2基团、--COOAlk基团或AlOk基团取代的苯基，其中Alk代表C.sub.1 -C.sub.4烷基；或R.sub.5代表一个--AlkN(Alk).sub.2基团，其中Alk如上定义；或一个SO.sub.2 R.sub.5基团，其中R.sub.5如上定义，以及当取代基R.sub.3包括氨基时，化合物的配制药学可接受酸盐。
• Novel benzopyranylpyrrolinone derivatives
  申请人：Researche Syntex France, S.A.

  公开号：US04997846A1

  公开（公告）日：1991-03-05

  Compounds of the formula ##STR1## wherein: R.sub.1 is cyano or nitro; R.sub.2 and R.sub.3 are independently hydrogen or lower alkyl; and R.sub.4 is alkyl; alkenyl; optionally substituted phenyl or phenyl lower alkyl; --(CH.sub.2).sub.m OR.sub.2 or --(CH.sub.2).sub.m N(R.sub.2).sub.2 ; wherein m is an integer of 1-5 and R.sub.2 is as defined above; or a pharmaceutically acceptable ester thereof; are smooth muscle relaxants, particularly useful in the treatment of hypertension.

  公式为##STR1##的化合物，其中：R.sub.1是氰基或硝基；R.sub.2和R.sub.3分别是氢或较低的烷基；R.sub.4是烷基；烯基；或者是可选择取代的苯基或苯基烷基；--(CH.sub.2).sub.m OR.sub.2或--(CH.sub.2).sub.m N(R.sub.2).sub.2；其中m是1-5的整数，R.sub.2如上所定义；或其药学上可接受的酯，是平滑肌松弛剂，特别适用于治疗高血压。
• Benzopyran compounds, processes for their production and pharmaceutical
  申请人：Kaken Pharmaceutical Co., Ltd.

  公开号：US05095016A1

  公开（公告）日：1992-03-10

  A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group or a R.sup.7 --CO-- group (wherein R.sup.7 is a C.sub.1-6 alkyl group, a phenyl group, a C.sub.2-6 alkenyl group which may be substituted by a phenyl group, or a C.sub.1-6 alkoxy group); R.sup.2 is a hydrogen atom, a substituted or unsubstituted C.sub.1-8 alkyl group, or a phenyl group; R.sup.3 is a hydrogen atom, and R.sup.4 is a hydroxyl group, or R.sup.3 and R.sup.4 together form a bond; each of R.sup.5 and R.sup.6 is a C.sub.1-4 alkyl group; and Y is a cyano group, a halogen atom, a nitro group, a C.sub.1-6 alkyl group, a C.sub.2-6 alkynyl group, a C.sub.1-6 alkylcarbonyl group, a C.sub.1-6 alkoxy group, a di-C.sub.1-6 alkylaminocarbonyl group, an aryl group, a C.sub.1-6 alkoxycarbonyl group, a carboxyl group or a morpholinocarbonyl group.

  化合物的式子(I): ##STR1## 或其药学上可接受的盐，其中： R.sup.1是氢原子，取代或未取代的C.sub.1-6烷基，C.sub.2-6烯基，C.sub.2-6炔基或R.sup.7--CO--基（其中R.sup.7是C.sub.1-6烷基，苯基，C.sub.2-6烯基，可以被苯基取代，或C.sub.1-6烷氧基）; R.sup.2是氢原子，取代或未取代的C.sub.1-8烷基或苯基; R.sup.3是氢原子，R.sup.4是羟基，或R.sup.3和R.sup.4一起形成键；R.sup.5和R.sup.6中的每一个是C.sub.1-4烷基；Y是氰基，卤素原子，硝基，C.sub.1-6烷基，C.sub.2-6炔基，C.sub.1-6烷基羰基，C.sub.1-6烷氧基，二C.sub.1-6烷基氨基羰基，芳基，C.sub.1-6烷氧羰基，羧基或吗啡啶羰基。